The Oncology Institute, Inc. (NASDAQ:TOI) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET
Company Participants
Mark Hueppelsheuser - General Counsel
Dan Virnich - Chief Executive Officer
Mihir Shah - Chief Financial Officer
Conference Call Participants
Taji Phillips - Jefferies
Operator
Good afternoon ladies and gentlemen and welcome to The Oncology Institute's Second Quarter 2023 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.
At this time, I'd like to turn the conference over to Mark Hueppelsheuser, General Counsel at TOI. Please go ahead sir.
Mark Hueppelsheuser
The press release announcing the Oncology Institute's results for the second quarter of 2023 are available at the Investors section of the company's website theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call.
Before we get started, I would like to remind you of the company's Safe Harbor language. Management may make forward-looking statements including guidance and underlying assumptions.
Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, see our filings with the SEC.
This call will also discuss non-GAAP financial measures such as adjusted EBITDA. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website.
Joining me on the call today is our CEO, Dan Virnich; and our CFO, Mihir Shah. Following our prepared remarks, we'll open the call for your questions.
With that, I'll turn the call over to Dan.
Dan Virnich
Thank you, Mark. Good afternoon everyone and thank you for joining our second quarter call. I'm honored to have the opportunity to serve as the next CEO of The Oncology Institute.
As noted in our June announcement, I took over as CEO on July 1st; and Brad Hively transitioned to the role of Vice Chairman where he remains on our Board and continues to provide strategic support for the organization.
Since this is my first earnings call as CEO of The Oncology Institute, I want to start by expressing my gratitude to our exceptional group of physicians and care teams. Their dedication to clinical care has made a profound impact on the lives of the patients we serve each day. It is because of their commitment that we achieved outstanding results in Q2 of 2023.